According to a recent study published in the journal Annals of Oncology, researchers from University of Texas MD Anderson Cancer Center in Houston, Texas, and Peter MacCallum Cancer Center in Melbourne, Australia, have found that the outcome of patients with mantle cell lymphoma who experience disease progression following ibrutinib therapy is poor.

Because there are a substantial number of patients with relapsed/refractory mantle cell lymphoma whose disease is resistant to ibrutinib, researchers sought to investigate the subsequent outcomes of such patients.

For the study, researchers identified 42 patients with a median age of 69 years with mantle cell lymphoma who discontinued ibrutinib treatment due to disease progression, toxicity, elective stem transplant in remission, or withdrawn consent. Patients had received a median of 6.5 cycles of ibrutinib.

Continue Reading

RELATED: Minimal Residual Disease Negativity Predicts Prognosis in Mantle Cell Lymphoma

Results showed that among 31 patients who experienced disease progression following ibrutinib and then underwent salvage therapy, the overall response rate was 32% and the complete response rate was 19%.

In addition, the median overall survival among those with disease progression was 8.4 months after a median follow-up of 10.7 months.

Researchers found that elevated serum lactate dehydrogenase at the time of disease progression was associated with decreased overall survival.


  1. Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv11